Targeting CDCP1 using function blocking monoclonal antibodies inhibits vascular metastasis of prostate cancer 26, intraperitoneal progression of ovarian cancer 13,27 and subcutaneous growth of lung and breast cancer 28 in mouse xenograft models. Here, CDCP1 is linked to breast carcinoma.